HMGB1 as a Potential Biomarker and Therapeutic Target for Severe COVID-19 The authors report that high mobility group box 1 (HMGB1), a prototypical damage-associated molecular pattern and a central mediator of lethal inflammation, could be a potential target for innovative therapeutic strategies for COVID-19. [Heliyon] |
|
| Researchers used a host-directed approach, which focused on cellular responses to diverse small-molecule treatments, to identify potentially effective drugs for COVID-19. [Heliyon] |
| MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Investigators report a patient with mycobacterial disease due to inherited deficiency of the transcription factor T-bet. Human T-bet deficiency underlaid mycobacterial disease by preventing the development of innate and innate-like adaptive lymphocytes. [Cell] |
|
|
|
| To identify host factors required for flavivirus infection, researchers performed full-genome loss of function CRISPR-Cas9 screens. Based on these results they focused their efforts on characterizing the roles that TMEM41B and VMP1 play in the virus replication cycle. [Cell] |
|
|
|
| Scientists demonstrated that SHP-1 inhibition improved CD11c+ cell-based vaccination against the parasite. They found increased cross-priming of CD8+ T lymphocytes in Leishmania-infected mice deficient for Mincle or with a selective loss of SHP-1 in CD11c+ cells. [Cell Reports] |
|
|
|
|
| The authors provide a comprehensive overview of neonatal–perinatal perspectives of COVID-19, ranging from the basic science of infection and recommendations for care of pregnant women and neonates to important psychosocial, ethical, and racial/ethnic topics emerging as a result of both the pandemic and the response of the healthcare community to the care of infected individuals. [Journal of Perinatology] |
|
|
|
|
| Pfizer, Inc. announced that the FDA accepted for priority review a Biologics License Application for its 20-valent pneumococcal conjugate vaccine candidate, as submitted for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults ages 18 years and older. [Pfizer, Inc. (BusinessWire, Inc)] |
|
|
|
| Rheonix, Inc. announced that the FDA has issued an expanded Emergency Use Authorization for the Rheonix COVID-19™ MDx Assay and now allows the use of saliva as an approved sample type. [Rheonix, Inc. (BusinessWire, Inc)] |
|
|
|
| Xlear filed a Pre-Emergency Use Authorization (Pre-EUA) request with the FDA. The Pre-EUA is a first step in seeking authorization of Xlear Nasal Spray as a new hygiene tool to help in combat the SARS-CoV-2 virus, the virus that causes COVID-19. [Xlear (BusinessWire, Inc)] |
|
|
|
|
| January 19 – 21, 2021 Virtual |
|
|
|
|
|
| University of Minnesota Medical School – Minneapolis, Minnesota, United States |
|
|
|
| The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| University of Nantes – Nantes, France |
|
|
|
| Queen’s University – Kingston, Ontario, Canada |
|
|
|
| Lerner Research Institute – Cleveland, Ohio, United States |
|
|
|
|